| Ashley T Lowe, FNP | |
|
701 Cashua Ferry Rd, Darlington, SC 29532-8488 | |
| (843) 391-2016 | |
| (843) 391-2026 |
| Full Name | Ashley T Lowe |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 21 Years |
| Location | 701 Cashua Ferry Rd, Darlington, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194768184 | NPI | - | NPPES |
| NP0813 | Medicaid | SC | |
| 003 | Other | SC | BCBS |
| 208552 | Other | SC | MEDCOST |
| AA13408552 | Other | SC | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 1910 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Florence, SC | Home health agency |
| Mcleod Health Cheraw | Cheraw, SC | Hospital |
| Mcleod Regional Medical Center-pee Dee | Florence, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcleod Health Cheraw | 7911228259 | 66 |
News Archive
People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.
A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 1 days ago
| Entity Name | Mcleod Regional Medical Center Of The Pee Dee, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427004738 PECOS PAC ID: 7416851852 Enrollment ID: O20040630000125 |
News Archive
People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.
A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 1 days ago
| Entity Name | Mcleod Physician Associates Ii |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801990494 PECOS PAC ID: 8224031307 Enrollment ID: O20060926000568 |
News Archive
People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.
A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 1 days ago
| Entity Name | Mcleod Health Cheraw |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275912974 PECOS PAC ID: 7911228259 Enrollment ID: O20151218002079 |
News Archive
People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.
A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley T Lowe, FNP Po Box 3239, Florence, SC 29502-3239 Ph: (843) 391-2016 | Ashley T Lowe, FNP 701 Cashua Ferry Rd, Darlington, SC 29532-8488 Ph: (843) 391-2016 |
News Archive
People who are diagnosed with cancer have a markedly increased risk of suicide and cardiovascular death during the period immediately after being given the diagnosis. This has been shown in a new study from Karolinska Institutet in Sweden, published in the prestigious scientific journal The New England Journal of Medicine.
A new American Cancer Society study finds that adult-onset cancer survivors run a greater risk of developing and dying from subsequent primary cancers (SPCs) than the general population.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 1 days ago
Jennifer Calabrese, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 105 Industrial Way, Darlington, SC 29532 Phone: 843-395-0015 Fax: 843-393-0971 | |
Mrs. Karen J Fulwood, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 110 Cherry St, Darlington, SC 29532 Phone: 843-968-3395 | |
Valorie Kern Barrett, D.N.P., APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 201 Cashua St, Darlington, SC 29532 Phone: 843-393-7452 Fax: 843-393-6210 | |
Mrs. Cathy M Gregory, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 305 Russell St, Darlington, SC 29532 Phone: 843-398-4400 | |
Melissa Felder, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 201 Cashua St, Darlington, SC 29532 Phone: 843-393-7452 Fax: 843-393-6210 | |
Dana Jones, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 157 Home Ave, Darlington, SC 29532 Phone: 843-432-2960 Fax: 843-773-6223 |